Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ludaxine is a **combination kit product** containing **bupivacaine hydrochloride**, **dexamethasone sodium phosphate**, **isopropyl alcohol**, and **povidone-iodine** for procedural analgesia and anesthesia. The pharmacologically active anesthetic component is bupivacaine hydrochloride, an amide local anesthetic that blocks voltage-gated sodium channels in peripheral nerves to inhibit action potential initiation and conduction, producing local and regional anesthesia. Dexamethasone sodium phosphate is a corticosteroid adjuvant commonly used to prolong the duration of nerve block analgesia, while isopropyl alcohol and povidone-iodine function as antiseptic skin-preparation components included with the kit rather than primary therapeutic analgesic agents. Publicly available information indicates this is a packaged procedural product listed on DailyMed rather than a distinct novel molecular entity; the exact commercial developer and formal regulatory approval status as a combination product are not clearly established from the provided evidence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine hydrochloride + isopropyl alcohol + dexamethasone sodium phosphate + povidone-iodine.